Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Seladelpar lysine by Gilead Sciences for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Seladelpar lysine is under clinical development by Gilead Sciences and currently in Pre-Registration for Primary Biliary Cholangitis (Primary Biliary Cirrhosis)....
Axicabtagene ciloleucel by Gilead Sciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According...
Axicabtagene ciloleucel by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....
Axicabtagene ciloleucel by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval
Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData,...
Axicabtagene ciloleucel by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...
Axicabtagene ciloleucel by Gilead Sciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...
Axicabtagene ciloleucel by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...
Risk adjusted net present value: What is the current valuation of Gilead Sciences's Seladelpar lysine?
Seladelpar lysine is a small molecule commercialized by Gilead Sciences, with a leading Pre-Registration program in Primary Biliary Cholangitis (Primary...
KITE-222 by Gilead Sciences for Mantle Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
KITE-222 by Gilead Sciences for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
KITE-222 by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...
KITE-222 by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
KITE-222 by Gilead Sciences for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
KITE-222 by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
KITE-222 by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...
GS-1720 by Gilead Sciences for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
GS-1720 is under clinical development by Gilead Sciences and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS)....
GS-0272 by Gilead Sciences for Systemic Lupus Erythematosus: Likelihood of Approval
GS-0272 is under clinical development by Gilead Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Gilead Sciences's KITE-222?
KITE-222 is a gene-modified cell therapy commercialized by Gilead Sciences, with a leading Phase II program in Primary Mediastinal B-Cell...
GS-6212 by Gilead Sciences for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
GS-6212 is under clinical development by Gilead Sciences and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS)....
Tilpisertib fosmecarbil by Gilead Sciences for Ulcerative Colitis: Likelihood of Approval
Tilpisertib fosmecarbil is under clinical development by Gilead Sciences and currently in Phase II for Ulcerative Colitis. According to GlobalData,...